Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine in Relapsed T-Cell and NK-Cell Lymphomas
NCT00416351Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2006
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of clofarabine in T-cell lymphoma, natural killer cell lymphoma (NKCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2006; status: completed.
02
Drugs
clofarabine
03
Conditions
T-cell lymphomanatural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT00416351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416351.